Lowering biologic doses for Crohn’s and ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 12 to 25 years
- Have Crohn’s disease (non-perianal) or ulcerative colitis
- Currently taking infliximab every 8 weeks or adalimumab every 2 weeks as their first anti-TNF, or a prior anti-TNF was stopped for reasons other than not working or later wearing off
- Have evidence of low gut inflammation recently (stool test calprotectin in the target range for the last 6 months, or recent endoscopy showing remission)
- Do not have active bowel symptoms right now, based on your IBD team’s judgment
- Not on steroid medicines (prednisone or budesonide) and not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
This trial tests whether a person's genetic makeup affects how well infliximab works for treating Crohn's disease. It may help doctors predict which patients benefit most from this medication.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
This trial tests three different types of biologic medications to find which works best as a first treatment for moderate-to-severe ulcerative colitis.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.